


# Treatment emergent peripheral neuropathy in the CASSIOPEIA trial

Cathelijne Fokkema,<sup>1</sup> Phillipe Moreau,<sup>2</sup> Bronno van der Holt,<sup>3</sup> Jérôme Lambert,<sup>4</sup> Mark van Duin,<sup>1</sup> Ruth Wester,<sup>1</sup> Joost L.M. Jongen,<sup>5</sup> Pieter A. van Doorn,<sup>5</sup> Sophie Godet,<sup>6</sup> KonSiong Jie,<sup>7</sup> Olivier Fitoussi,<sup>8</sup> Michel Delforge,<sup>9</sup> Awa Keita-Manta,<sup>10</sup> Odile Luycx,<sup>11</sup> Tom Cupedo,<sup>1</sup> Niels W.C.J. van de Donk,<sup>12</sup> Sonja Zweegman,<sup>12</sup> Jessica T. Vermeulen,<sup>13</sup> Pieter Sonneveld<sup>1</sup> and Annemiek Broijl<sup>1</sup>


<sup>1</sup>Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; <sup>2</sup>Hematology Department, University Hospital Hôtel-Dieu, Nantes, France; <sup>3</sup>HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; <sup>4</sup>Biostatistical Department, Hospital Saint Louis, Paris, France; <sup>5</sup>Department of Neurology, Erasmus MC, Rotterdam, the Netherlands; <sup>6</sup>Department of Hematology, University Hospital of Reims and UFR Médecine, Reims, France; <sup>7</sup>Department of Hematology, Zuyderland MC, Sittard, the Netherlands; <sup>8</sup>Department of Hematology, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France; <sup>9</sup>Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium; <sup>10</sup>Premier Research, CRO, Paris, France; <sup>11</sup>Department of Hematology, Hospital Scorff Hospital Group Bretagne Sud, Lorient, France; <sup>12</sup>Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, the Netherlands and <sup>13</sup>Janssen Research & Development, LLC, Leiden, the Netherlands

Correspondence: A. BROIJL - a.broyl@erasmusmc.nl  
<https://doi.org/10.3324/haematol.2021.280567>

Supplementary Figure 1




## Supplementary Figure 2




### Supplementary figure 3


A)



B)



c)



## Supplementary Figure Legends

### **Supplementary Figure 1** CASSIOPEIA trial design

*VTD, bortezomib, thalidome, and dexamathesone; DARA, daratumumab; PR, partial response; PD, progressive disease; Q8W, every 8 weeks.*

### **Supplementary Figure 2** Flow diagram of patients included in landmark analysis

\* PNP grade  $\geq 2$  from start induction till start consolidation

\*\* Patients who develop the first grade 2 PNP event during consolidation therapy are included in this group

### **Supplementary Figure 3** Kaplan-Meier curves of progression-free survival from start mobilisation

A) Progression-free survival of patients experiencing treatment emergent peripheral neuropathy during induction with and without dose modification of thalidomide and/or bortezomib. (Yes versus No)

B) Progression-free survival of patients experiencing treatment emergent peripheral neuropathy during induction with and without dose modification of thalidomide. (Yes versus No)

C) Progression-free survival of patients experiencing treatment emergent peripheral neuropathy during induction with and without dose modification of bortezomib. (Yes versus No)